Exec Chat: Binah.ai CEO And Founder Discusses Racial Disparities In Clinical Trials
Executive Summary
David Maman is the CEO and founder of Binah.ai, a provider of video-based health monitoring tools powered by artificial intelligence. Maman shared with Medtech Insight his thoughts on the FDA’s recent guidance to increase racial and ethnic diversity in clinical trials.
You may also be interested in...
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.
More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths
Abbott initiated a recall in February of thousands of Heartmate devices due to a system obstruction that can result in serious health outcomes, including death. The FDA has now designated the recall as class I.
Mini-Slings Are Comparable To Traditional Ones To Treat Incontinence, FDA Says
The US FDA continues to provide updates on the safety and efficacy of surgical mesh sling procedures, a common surgery to correct stress urinary incontinence.